Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Feasibility, Safety, and Activity Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects With Previously Treated Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1/2 Feasibility, Safety, and Activity Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects With Previously Treated Advanced Solid Tumors

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 26 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BPX 601 (Primary) ; Cyclophosphamide; Fludarabine; Rimiducid
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Pancreatic cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Bellicum Pharmaceuticals

Most Recent Events

  • 23 Feb 2026 Status changed from suspended to discontinued.
  • 14 Mar 2023 Status changed to discontinued, according to a Bellicum Pharmaceuticals media release.
  • 14 Mar 2023 According to a Bellicum Pharmaceuticals media release, company is communicating with clinical trial sites and regulatory agencies regarding its decision to discontinue its trials, and an evaluation of the Company's strategic alternatives is underway.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top